Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ehamparanathan A"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Augusto, Karen K. L., Crapnell, Robert D., Bernalte, Elena, Zighed, Sabri, Ehamparanathan, Anbuchselvan, Pimlott, Jessica L., Andrews, Hayley G., Whittingham, Matthew J., Rowley-Neale, Samuel J., Fatibello-Filho, Orlando, Banks, Craig E.
Publikováno v:
Microchimica Acta; Jul2024, Vol. 191 Issue 7, p1-14, 14p
Autor:
Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Peifeng Tang, Laurel Hoffman, June Kuang, Peiran Liu, Chao Huang, Cheng Du, Li Tao, Letha Chemmalil, Angela Lewandowski, Sanchayita Ghose, Zheng Jian Li, Shijie Liu
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s
Externí odkaz:
https://doaj.org/article/18ea0b2eb9fc414ebf9fd1ddbcf039cb
Autor:
Peifeng Tang, Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Laurel Hoffman, Cheng Du, Yuanli Song, Li Tao, Angela Lewandowski, Sanchayita Ghose, Zheng Jian Li, Shijie Liu
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Disulfide bonds play a crucial role in folding and structural stabilization of monoclonal antibodies (mAbs). Disulfide bond reduction may happen during the mAb manufacturing process, resulting in low molecular weight species and possible failure to m
Externí odkaz:
https://doaj.org/article/c3dc9748a0654796b05a080bcd584973
Antibody disulfide bond reduction and recovery during biopharmaceutical process development-A review
Autor:
Sanchayita Ghose, Vivekh Ehamparanathan, Tingwei Ren, Zheng Jian Li, Zhijun Tan, Angela Lewandowski
Publikováno v:
Biotechnology and bioengineeringREFERENCES. 118(8)
Antibody disulfide bond reduction has been a challenging issue in monoclonal antibody manufacturing. It could lead to a decrease of product purity and failure to meet the targeted product profile and/or specifications. More importantly, disulfide bon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d8b9ba965f36cda7467d17e88ae7f3
https://pubmed.ncbi.nlm.nih.gov/33844277
https://pubmed.ncbi.nlm.nih.gov/33844277
Autor:
Graham Easton, Nisha Ehamparanathan, Dason Evans, Devina Raval, Riya Elizabeth George, S. Elizabeth Wright, Harriet Le Voir, Harvey Wells, Helen Bintley, Ashia Shafi, Angela Rowlands
Publikováno v:
MedEdPublish. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::576c42b08e8d5a52caa35b83dc2d5b84
https://doi.org/10.15694/mep.2021.000027.1
https://doi.org/10.15694/mep.2021.000027.1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Li Tao, Shijie Liu, Vivekh Ehamparanathan, Cheng Du, Zheng Jian Li, Angela Lewandowski, Laurel Hoffman, Sanchayita Ghose, Yuanli Song, Tingwei Ren, Zhijun Tan, Peifeng Tang
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Disulfide bonds play a crucial role in folding and structural stabilization of monoclonal antibodies (mAbs). Disulfide bond reduction may happen during the mAb manufacturing process, resulting in low molecular weight species and possible failure to m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b85ae209df75c3fd1e664a5e0217843e
https://pubmed.ncbi.nlm.nih.gov/33031716
https://pubmed.ncbi.nlm.nih.gov/33031716
Autor:
Zheng Jian Li, Peiran Liu, Peifeng Tang, Zhijun Tan, June Kuang, Shijie Liu, Letha Chemmalil, Angela Lewandowski, Laurel Hoffman, Li Tao, Sanchayita Ghose, Chao Huang, Vivekh Ehamparanathan, Cheng Du, Tingwei Ren
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce482db70c542c34bddf2efa362e2dbb
https://pubmed.ncbi.nlm.nih.gov/33016217
https://pubmed.ncbi.nlm.nih.gov/33016217
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.